SAVA Secures €7.4 Million in Seed Funding to Transform Health Monitoring Landscape
June 22, 2024, 3:31 am
Location: United Kingdom, England, London
Employees: 11-50
Founded date: 2016
Total raised: $8M
In a groundbreaking move, London-based startup SAVA has successfully raised over €7.4 million in Seed funding to revolutionize the realm of health monitoring. Co-founded by Renato Circi and Rafael Michali, both esteemed bioengineers from Imperial College London, SAVA is poised to disrupt the status quo with its cutting-edge microsensor technology. This real-time, affordable, and painless innovation is set to redefine how individuals manage their health, starting with glucose monitoring for those with diabetes.
The significance of SAVA's microsensor technology cannot be overstated, especially in light of the staggering statistics projecting that 1 in 8 adults, approximately 783 million people, will be impacted by diabetes by 2045. As healthcare institutions worldwide increasingly adopt continuous glucose monitoring (CGM) as the standard of care for diabetes management, SAVA's timely entry into the market holds immense promise.
Having recently obtained approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to conduct clinical trials on diabetic patients, SAVA is on the cusp of validating its groundbreaking technology on a larger scale. The rigorous validation process undertaken by the MHRA underscores the safety, performance, and design excellence of SAVA's microsensor, setting the stage for a transformative shift in healthcare delivery.
Beyond glucose monitoring, SAVA's modular design paves the way for simultaneous monitoring of multiple molecules, unlocking a myriad of possibilities in chronic disease management, personalized therapy, and overall well-being. With a vision to empower individuals to take control of their health through seamless access to real-time health insights, SAVA is poised to usher in a new era of preventative healthcare.
The recent funding round, led by Balderton Capital and Exor Ventures, brings SAVA's total raised capital to $13 million, a testament to the confidence and support garnered from leading VC firms, angel investors, and governmental entities. This financial infusion will fuel team expansion, product development, and clinical performance demonstrations, propelling SAVA to the forefront of the healthcare innovation landscape.
Renato Circi, co-founder of SAVA, expressed the company's mission succinctly, stating, "At SAVA, we are tackling preventable illness by building a new operating system for health monitoring." This ethos underscores SAVA's commitment to democratizing world-class monitoring technology and ushering in a paradigm shift towards preventative, personalized, and painless healthcare.
In a similar vein, Rafael Michali, co-founder of SAVA, articulated the company's vision for transforming healthcare from a curative to a preventative system, emphasizing the pivotal role of real-time health insights in empowering individuals to proactively manage their well-being. With a user-centric approach and a focus on chronic disease management and preventative care, SAVA is poised to redefine the healthcare landscape.
James Wise, Partner at Balderton Capital, lauded SAVA's potential to become a defining product in personal health monitoring, highlighting the critical role it can play in diagnosing and treating chronic diseases. The endorsement from industry experts underscores the transformative impact that SAVA's technology can have on healthcare delivery and patient outcomes.
As SAVA embarks on its journey to reshape the healthcare landscape, it stands as a beacon of innovation, empowerment, and accessibility in an industry ripe for disruption. With a commitment to preventative, personalized, and painless healthcare, SAVA is poised to lead the charge towards a future where health monitoring is not just a necessity but a seamless and empowering experience for all.
The significance of SAVA's microsensor technology cannot be overstated, especially in light of the staggering statistics projecting that 1 in 8 adults, approximately 783 million people, will be impacted by diabetes by 2045. As healthcare institutions worldwide increasingly adopt continuous glucose monitoring (CGM) as the standard of care for diabetes management, SAVA's timely entry into the market holds immense promise.
Having recently obtained approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to conduct clinical trials on diabetic patients, SAVA is on the cusp of validating its groundbreaking technology on a larger scale. The rigorous validation process undertaken by the MHRA underscores the safety, performance, and design excellence of SAVA's microsensor, setting the stage for a transformative shift in healthcare delivery.
Beyond glucose monitoring, SAVA's modular design paves the way for simultaneous monitoring of multiple molecules, unlocking a myriad of possibilities in chronic disease management, personalized therapy, and overall well-being. With a vision to empower individuals to take control of their health through seamless access to real-time health insights, SAVA is poised to usher in a new era of preventative healthcare.
The recent funding round, led by Balderton Capital and Exor Ventures, brings SAVA's total raised capital to $13 million, a testament to the confidence and support garnered from leading VC firms, angel investors, and governmental entities. This financial infusion will fuel team expansion, product development, and clinical performance demonstrations, propelling SAVA to the forefront of the healthcare innovation landscape.
Renato Circi, co-founder of SAVA, expressed the company's mission succinctly, stating, "At SAVA, we are tackling preventable illness by building a new operating system for health monitoring." This ethos underscores SAVA's commitment to democratizing world-class monitoring technology and ushering in a paradigm shift towards preventative, personalized, and painless healthcare.
In a similar vein, Rafael Michali, co-founder of SAVA, articulated the company's vision for transforming healthcare from a curative to a preventative system, emphasizing the pivotal role of real-time health insights in empowering individuals to proactively manage their well-being. With a user-centric approach and a focus on chronic disease management and preventative care, SAVA is poised to redefine the healthcare landscape.
James Wise, Partner at Balderton Capital, lauded SAVA's potential to become a defining product in personal health monitoring, highlighting the critical role it can play in diagnosing and treating chronic diseases. The endorsement from industry experts underscores the transformative impact that SAVA's technology can have on healthcare delivery and patient outcomes.
As SAVA embarks on its journey to reshape the healthcare landscape, it stands as a beacon of innovation, empowerment, and accessibility in an industry ripe for disruption. With a commitment to preventative, personalized, and painless healthcare, SAVA is poised to lead the charge towards a future where health monitoring is not just a necessity but a seamless and empowering experience for all.